OvaWatch, Multiplex Biomarker for Ovarian cancer Risk Assessment
Ovarian cancer is one of the most common gynecological cancers and it has a poor prognosis. Due to the lack of a specific blood-based biomarker for ovarian cancer, early-stage diagnosis is often missed. The OvaWatch is a comprehensive ovarian cancer risk assessment testing that is based on the correlation of seven ovarian tumor markers with the age and menopausal status of the patient. These markers include apolipoprotein A1, β2-microglobulin, CA 125, pre albumin, transferrin, HE4 (human epididymis protein 4), and follicle-stimulating hormone.
Results are reported as ovarian cancer risk scores ranging from 0.0 to 10.0 together with the serum concentrations of CA 125 and HE4. Positive and negative predictive values are also assigned based on the risk scores of the patient. This test, as with OVA1, ROMA, RMI, ADNEX and OVERA are not recommended by the NCCN or other societies in determining the status of an undiagnosed adnexal mass. Further, these tests should not be used alone to decide whether to proceed with surgical exploration for an adnexal mass.
- Useful in the evaluation of an adnexal mass for ovarian cancer
- Helpful in monitoring therapeutic efficacy for ovarian cancer
Higher risk scores indicate a higher probability of the adnexal mass being malignant and biopsy is suggested.
Lower risk scores indicate a higher probability of the adnexal mass being benign.
Risk score <5: Low probability of malignancy
Risk score ≤ 5: Indeterminate
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum; serum separator tube (SST).
Stability
- Ambient: 24 hrs.
- Refrigerated: 7-14 days
- Frozen: 30 days
- Front Med (Lausanne). 2023 Jan 23;10:1102437 [PMID: 36756174]
- Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11. [PMID: 26970494]
- Obstet Gynecol. 2007 Oct;110(4):841-8 [PMID: 17906018]
- J Midlife Health. 2020 Oct-Dec;11(4):217-223. [PMID: 33767562]